STOCK TITAN

[8-K] flyExclusive, Inc. Reports Material Event

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Atomico Advisors IV, Ltd. and its affiliated funds have filed a Schedule 13G disclosing a passive ownership position in Hinge Health, Inc. (HNGE) following the company’s 23 May 2025 IPO.

  • Aggregate beneficial ownership: 6,713,063 Class B shares, convertible 1-for-1 into Class A.
  • Economic stake equals 8.3 % of the 80,597,784 total shares outstanding post-IPO.
  • All voting and dispositive power is reported as shared; no sole power.
  • Class B shares carry 15 votes per share, giving Atomico considerably greater voting influence than its economic interest implies; this higher voting weight is not reflected in the 8.3 % figure because percentages are shown on an as-converted basis.
  • The filing is made under Rule 13d-1(c)/(d), indicating a passive investment intent with no activist agenda disclosed.

The disclosure confirms that a prominent venture investor has retained a meaningful stake through the IPO. While it does not change financial outlook, the dual-class structure heightens governance concentration, a consideration for shareholders assessing control dynamics.

Atomico Advisors IV, Ltd. e i suoi fondi affiliati hanno presentato un Schedule 13G, dichiarando una posizione di proprietà passiva in Hinge Health, Inc. (HNGE) a seguito dell'IPO della società del 23 maggio 2025.

  • Proprietà beneficiaria aggregata: 6.713.063 azioni di Classe B, convertibili 1 a 1 in azioni di Classe A.
  • La partecipazione economica corrisponde a 8,3% delle 80.597.784 azioni totali in circolazione dopo l'IPO.
  • Tutti i poteri di voto e dispositivi sono dichiarati come condivisi; nessun potere esclusivo.
  • Le azioni di Classe B attribuiscono 15 voti per azione, conferendo ad Atomico un'influenza di voto molto maggiore rispetto alla sua partecipazione economica; questo peso di voto più elevato non è riflesso nella percentuale dell'8,3% perché le percentuali sono calcolate su base convertita.
  • La comunicazione è stata effettuata ai sensi della Regola 13d-1(c)/(d), indicando un intento di investimento passivo senza alcuna agenda attivista dichiarata.

La divulgazione conferma che un importante investitore di venture capital ha mantenuto una quota significativa attraverso l'IPO. Sebbene non modifichi le prospettive finanziarie, la struttura a doppia classe aumenta la concentrazione del controllo, un aspetto da considerare per gli azionisti che valutano le dinamiche di governance.

Atomico Advisors IV, Ltd. y sus fondos afiliados han presentado un Schedule 13G revelando una posición de propiedad pasiva en Hinge Health, Inc. (HNGE) tras la oferta pública inicial (IPO) de la empresa el 23 de mayo de 2025.

  • Propiedad beneficiaria agregada: 6,713,063 acciones Clase B, convertibles 1 a 1 en Clase A.
  • La participación económica equivale al 8.3% de las 80,597,784 acciones totales en circulación después de la IPO.
  • Todo el poder de voto y disposición se reporta como compartido; sin poder exclusivo.
  • Las acciones Clase B otorgan 15 votos por acción, lo que da a Atomico una influencia de voto considerablemente mayor que su interés económico; este mayor peso de voto no se refleja en el 8.3% porque los porcentajes se muestran en base a la conversión.
  • La presentación se realiza bajo la Regla 13d-1(c)/(d), indicando una intención de inversión pasiva sin agenda activista declarada.

La divulgación confirma que un destacado inversor de capital riesgo ha mantenido una participación significativa a través de la IPO. Aunque no cambia las perspectivas financieras, la estructura de doble clase aumenta la concentración del control, un aspecto a considerar para los accionistas que evalúan las dinámicas de control.

Atomico Advisors IV, Ltd.와 그 계열 펀드들은 2025년 5월 23일 회사의 IPO 이후 Hinge Health, Inc. (HNGE)에 대한 수동적 소유 지분을 공시하는 Schedule 13G를 제출했습니다.

  • 총 수익적 소유: 6,713,063 클래스 B 주식, 1대1로 클래스 A로 전환 가능.
  • 경제적 지분은 IPO 후 발행된 총 80,597,784주 중 8.3%에 해당합니다.
  • 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 단독 권한은 없습니다.
  • 클래스 B 주식은 주당 15표의 의결권을 가지며, 이는 Atomico가 경제적 지분보다 훨씬 큰 의결 영향력을 가진다는 의미입니다. 이 높은 의결권 가중치는 8.3% 수치에는 반영되지 않았는데, 이는 비율이 전환 기준으로 계산되었기 때문입니다.
  • 이 공시는 Rule 13d-1(c)/(d)에 따라 제출되었으며, 수동적 투자 의도를 나타내며 활동가적 의도는 공개되지 않았습니다.

이번 공시는 저명한 벤처 투자자가 IPO를 통해 상당한 지분을 유지하고 있음을 확인해 줍니다. 재무 전망에는 변화가 없으나, 이중 클래스 구조는 지배구조 집중도를 높여 주주들이 지배력 역학을 평가할 때 고려해야 할 요소입니다.

Atomico Advisors IV, Ltd. et ses fonds affiliés ont déposé un Schedule 13G révélant une position de propriété passive dans Hinge Health, Inc. (HNGE) suite à l'introduction en bourse de la société le 23 mai 2025.

  • Participation bénéficiaire agrégée : 6 713 063 actions de Classe B, convertibles en actions de Classe A à raison de 1 pour 1.
  • La part économique représente 8,3 % des 80 597 784 actions totales en circulation après l'IPO.
  • Tous les pouvoirs de vote et de disposition sont déclarés comme partagés ; aucun pouvoir exclusif.
  • Les actions de Classe B donnent 15 voix par action, conférant à Atomico une influence de vote bien supérieure à son intérêt économique ; ce poids de vote plus élevé n'est pas reflété dans le chiffre de 8,3 % car les pourcentages sont indiqués sur une base convertie.
  • Le dépôt est effectué en vertu de la règle 13d-1(c)/(d), indiquant une intention d'investissement passive sans agenda activiste déclaré.

Cette divulgation confirme qu'un investisseur en capital-risque de premier plan a conservé une participation significative lors de l'IPO. Bien que cela ne modifie pas les perspectives financières, la structure à double catégorie d'actions accentue la concentration du contrôle, un élément à prendre en compte pour les actionnaires évaluant la dynamique du contrôle.

Atomico Advisors IV, Ltd. und seine verbundenen Fonds haben eine Schedule 13G eingereicht, in der sie eine passive Beteiligungsposition an Hinge Health, Inc. (HNGE) nach dem Börsengang des Unternehmens am 23. Mai 2025 offenlegen.

  • Gesamtnutzungsanteil: 6.713.063 Class B Aktien, die 1:1 in Class A Aktien wandelbar sind.
  • Der wirtschaftliche Anteil entspricht 8,3 % der insgesamt 80.597.784 nach dem Börsengang ausstehenden Aktien.
  • Alle Stimm- und Verfügungsrechte werden als geteilt gemeldet; keine alleinigen Rechte.
  • Class B Aktien haben 15 Stimmen pro Aktie, was Atomico eine deutlich größere Stimmkraft als den wirtschaftlichen Anteil verleiht; dieses höhere Stimmgewicht spiegelt sich nicht in der 8,3 % Zahl wider, da die Prozentsätze auf umgerechneter Basis angegeben sind.
  • Die Meldung erfolgt gemäß Regel 13d-1(c)/(d) und signalisiert eine passive Investitionsabsicht ohne eine aktivistische Agenda.

Die Offenlegung bestätigt, dass ein prominenter Risikokapitalgeber eine bedeutende Beteiligung durch den Börsengang gehalten hat. Obwohl dies die finanzielle Prognose nicht ändert, erhöht die Dual-Class-Struktur die Konzentration der Kontrolle, was für Aktionäre bei der Bewertung der Kontrollverhältnisse zu beachten ist.

Positive
  • Atomico Advisors IV disclosed a sizable 6.7 M-share, 8.3 % stake, signaling continued confidence in Hinge Health post-IPO
  • Presence of a well-known venture firm may be viewed favorably by other investors and partners
Negative
  • Dual-class structure grants 15x voting power, concentrating governance and potentially diluting minority influence
  • No financial metrics, strategic initiatives, or additional capital commitments were provided

Insights

TL;DR: Atomico holds 8.3 % of HNGE, boosting voting power via 15-vote Class B shares; information is noteworthy but not thesis-changing.

The 13G shows Atomico kept 6.7 M shares after Hinge Health’s IPO, translating to an 8.3 % economic stake. Because these are Class B shares with 15 votes each, Atomico’s effective influence could exceed 30 % of total voting rights, reinforcing the founders’ and early investors’ control. The filing is passive, so no immediate strategic shift is implied. Investors may view continued backing from a top-tier VC as a confidence signal, but absent financial data or transaction terms, the event is modestly informative rather than valuation-moving.

Atomico Advisors IV, Ltd. e i suoi fondi affiliati hanno presentato un Schedule 13G, dichiarando una posizione di proprietà passiva in Hinge Health, Inc. (HNGE) a seguito dell'IPO della società del 23 maggio 2025.

  • Proprietà beneficiaria aggregata: 6.713.063 azioni di Classe B, convertibili 1 a 1 in azioni di Classe A.
  • La partecipazione economica corrisponde a 8,3% delle 80.597.784 azioni totali in circolazione dopo l'IPO.
  • Tutti i poteri di voto e dispositivi sono dichiarati come condivisi; nessun potere esclusivo.
  • Le azioni di Classe B attribuiscono 15 voti per azione, conferendo ad Atomico un'influenza di voto molto maggiore rispetto alla sua partecipazione economica; questo peso di voto più elevato non è riflesso nella percentuale dell'8,3% perché le percentuali sono calcolate su base convertita.
  • La comunicazione è stata effettuata ai sensi della Regola 13d-1(c)/(d), indicando un intento di investimento passivo senza alcuna agenda attivista dichiarata.

La divulgazione conferma che un importante investitore di venture capital ha mantenuto una quota significativa attraverso l'IPO. Sebbene non modifichi le prospettive finanziarie, la struttura a doppia classe aumenta la concentrazione del controllo, un aspetto da considerare per gli azionisti che valutano le dinamiche di governance.

Atomico Advisors IV, Ltd. y sus fondos afiliados han presentado un Schedule 13G revelando una posición de propiedad pasiva en Hinge Health, Inc. (HNGE) tras la oferta pública inicial (IPO) de la empresa el 23 de mayo de 2025.

  • Propiedad beneficiaria agregada: 6,713,063 acciones Clase B, convertibles 1 a 1 en Clase A.
  • La participación económica equivale al 8.3% de las 80,597,784 acciones totales en circulación después de la IPO.
  • Todo el poder de voto y disposición se reporta como compartido; sin poder exclusivo.
  • Las acciones Clase B otorgan 15 votos por acción, lo que da a Atomico una influencia de voto considerablemente mayor que su interés económico; este mayor peso de voto no se refleja en el 8.3% porque los porcentajes se muestran en base a la conversión.
  • La presentación se realiza bajo la Regla 13d-1(c)/(d), indicando una intención de inversión pasiva sin agenda activista declarada.

La divulgación confirma que un destacado inversor de capital riesgo ha mantenido una participación significativa a través de la IPO. Aunque no cambia las perspectivas financieras, la estructura de doble clase aumenta la concentración del control, un aspecto a considerar para los accionistas que evalúan las dinámicas de control.

Atomico Advisors IV, Ltd.와 그 계열 펀드들은 2025년 5월 23일 회사의 IPO 이후 Hinge Health, Inc. (HNGE)에 대한 수동적 소유 지분을 공시하는 Schedule 13G를 제출했습니다.

  • 총 수익적 소유: 6,713,063 클래스 B 주식, 1대1로 클래스 A로 전환 가능.
  • 경제적 지분은 IPO 후 발행된 총 80,597,784주 중 8.3%에 해당합니다.
  • 모든 의결권 및 처분 권한은 공동 보유로 보고되었으며, 단독 권한은 없습니다.
  • 클래스 B 주식은 주당 15표의 의결권을 가지며, 이는 Atomico가 경제적 지분보다 훨씬 큰 의결 영향력을 가진다는 의미입니다. 이 높은 의결권 가중치는 8.3% 수치에는 반영되지 않았는데, 이는 비율이 전환 기준으로 계산되었기 때문입니다.
  • 이 공시는 Rule 13d-1(c)/(d)에 따라 제출되었으며, 수동적 투자 의도를 나타내며 활동가적 의도는 공개되지 않았습니다.

이번 공시는 저명한 벤처 투자자가 IPO를 통해 상당한 지분을 유지하고 있음을 확인해 줍니다. 재무 전망에는 변화가 없으나, 이중 클래스 구조는 지배구조 집중도를 높여 주주들이 지배력 역학을 평가할 때 고려해야 할 요소입니다.

Atomico Advisors IV, Ltd. et ses fonds affiliés ont déposé un Schedule 13G révélant une position de propriété passive dans Hinge Health, Inc. (HNGE) suite à l'introduction en bourse de la société le 23 mai 2025.

  • Participation bénéficiaire agrégée : 6 713 063 actions de Classe B, convertibles en actions de Classe A à raison de 1 pour 1.
  • La part économique représente 8,3 % des 80 597 784 actions totales en circulation après l'IPO.
  • Tous les pouvoirs de vote et de disposition sont déclarés comme partagés ; aucun pouvoir exclusif.
  • Les actions de Classe B donnent 15 voix par action, conférant à Atomico une influence de vote bien supérieure à son intérêt économique ; ce poids de vote plus élevé n'est pas reflété dans le chiffre de 8,3 % car les pourcentages sont indiqués sur une base convertie.
  • Le dépôt est effectué en vertu de la règle 13d-1(c)/(d), indiquant une intention d'investissement passive sans agenda activiste déclaré.

Cette divulgation confirme qu'un investisseur en capital-risque de premier plan a conservé une participation significative lors de l'IPO. Bien que cela ne modifie pas les perspectives financières, la structure à double catégorie d'actions accentue la concentration du contrôle, un élément à prendre en compte pour les actionnaires évaluant la dynamique du contrôle.

Atomico Advisors IV, Ltd. und seine verbundenen Fonds haben eine Schedule 13G eingereicht, in der sie eine passive Beteiligungsposition an Hinge Health, Inc. (HNGE) nach dem Börsengang des Unternehmens am 23. Mai 2025 offenlegen.

  • Gesamtnutzungsanteil: 6.713.063 Class B Aktien, die 1:1 in Class A Aktien wandelbar sind.
  • Der wirtschaftliche Anteil entspricht 8,3 % der insgesamt 80.597.784 nach dem Börsengang ausstehenden Aktien.
  • Alle Stimm- und Verfügungsrechte werden als geteilt gemeldet; keine alleinigen Rechte.
  • Class B Aktien haben 15 Stimmen pro Aktie, was Atomico eine deutlich größere Stimmkraft als den wirtschaftlichen Anteil verleiht; dieses höhere Stimmgewicht spiegelt sich nicht in der 8,3 % Zahl wider, da die Prozentsätze auf umgerechneter Basis angegeben sind.
  • Die Meldung erfolgt gemäß Regel 13d-1(c)/(d) und signalisiert eine passive Investitionsabsicht ohne eine aktivistische Agenda.

Die Offenlegung bestätigt, dass ein prominenter Risikokapitalgeber eine bedeutende Beteiligung durch den Börsengang gehalten hat. Obwohl dies die finanzielle Prognose nicht ändert, erhöht die Dual-Class-Struktur die Konzentration der Kontrolle, was für Aktionäre bei der Bewertung der Kontrollverhältnisse zu beachten ist.

false0001843973x0001843973us-gaap:WarrantMember2025-07-302025-07-3000018439732025-07-302025-07-300001843973us-gaap:CommonClassAMember2025-07-302025-07-30

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

____________________

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) July 30, 2025

flyExclusive, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40444

86-1740840

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

 

2860 Jetport Road,

Kinston, NC

28504

(Address of principal executive offices)

(Zip Code)

252-208-7715

Registrant’s telephone number, including area code

Not Applicable

(Former name or former address, if changed since last report.)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

x

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Class A Common Stock

 

FLYX

 

NYSE American LLC

Redeemable warrants, each whole warrant

exercisable for one share of Class A Common

Stock at an exercise price of $11.50 per share

 

FLYX WS

 

NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

 


 

Item 1.01 Entry into a Material Agreement.

 

As previously reported, on February 13, 2025, flyExclusive, Inc., a Delaware corporation (“flyExclusive”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) by and among flyExclusive, FlyX Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of flyExclusive (“Merger Sub”), Jet.AI Inc., a Delaware corporation (“Jet.AI”) and Jet.AI SpinCo, Inc., a Delaware corporation, and a wholly owned subsidiary of Jet.AI (“SpinCo”), pursuant to which (i) as a condition to closing the transaction, Jet.AI will distribute all of the shares of SpinCo, on a pro rata basis, to the stockholders of Jet.AI (the “Distribution”) and (ii) the Merger Sub will merge with and into SpinCo (the “Merger” and, together with the Distribution and all other transactions contemplated under the Merger Agreement, the “Transactions”) with SpinCo surviving the Merger as a wholly owned subsidiary of flyExclusive.

Also as previously reported, on May 6, 2025, the parties to the Merger Agreement entered into an Amended and Restated Agreement and Plan of Merger and Reorganization (the “A&R Merger Agreement”).

On July 30, 2025, the parties executed Amendment No. 1 to the Amended and Restated Agreement and Plan of Merger and Reorganization to extend the Outside Date from June 30, 2025 to October 31, 2025.

Additional Information and Where to Find It

In connection with the proposed Transactions, flyExclusive has filed relevant materials with the SEC, including a registration statement on Form S-4, which include a proxy statement/prospectus. After the registration statement is declared effective by the SEC, the definitive proxy statement/prospectus and other relevant documents will be mailed to the stockholders of Jet.AI as of the record date established for voting on the proposed Transactions and will contain important information about the proposed Transactions and related matters. Stockholders of Jet.AI and other interested persons are advised to read, when available, these materials (including any amendments or supplements thereto) and any other relevant documents in connection with Jet.AI’s solicitation of proxies for the meeting of stockholders to be held to approve, among other things, the proposed Transactions because they will contain important information about flyExclusive, Merger Sub, Jet.AI, SpinCo and the proposed Transactions. Stockholders will also be able to obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus and other relevant materials in connection with the transaction without charge, once available, at the SEC’s website at www.sec.gov.

Participants in Solicitation

Jet.AI and its respective directors and executive officers may be deemed participants in the solicitation of proxies from Jet.AI’s shareholders in connection with the proposed Transactions. Jet.AI’s shareholders and other interested persons may obtain, without charge, more detailed information regarding the directors and officers of Jet.AI as reflected in the annual report on Form 10-K for the period ended December 31, 2023, filed with the SEC on April 1, 2024, and amended on April 29, 2024 and August 15, 2024. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Jet.AI’s shareholders in connection with the proposed Transactions will be set forth in the proxy statement/prospectus for the proposed Transactions when available. Additional information regarding the interests of participants in the solicitation of proxies in connection with the proposed Transactions will be included in the proxy statement/prospectus that flyExclusive intends to file with the SEC. You may obtain free copies of these documents as described in the preceding paragraph.

flyExclusive, Merger Sub and their respective directors and executive officers may also be deemed to be participants in the solicitation of proxies from the shareholders of Jet.AI in connection with the proposed Transactions. A list of the names of such directors and executive officers and information regarding their interests in the proposed Transactions will be included in the proxy statement/prospectus for the proposed Transactions when available.

No Solicitation or Offer

This communication shall neither constitute an offer to sell nor the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval in any jurisdiction in connection with the Transactions, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to any registration or qualification under the securities laws of any such jurisdictions. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation.

 

 

2

 


 

Forward-Looking Statements Legend

This communication contains forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. All statements other than statements of historical facts contained in this communication, including statements regarding the expected timing and structure of the Transactions, the ability of the parties to complete the Transactions, the expected benefits of the Transactions, the tax consequences of the Transactions, and flyExclusive’s future results of operations and financial position, business strategy and its expectations regarding the benefits of the Transactions. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside the control of flyExclusive and Jet.AI, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include, but are not limited to: the risk that the proposed Transactions may not be completed in a timely manner or at all, which may adversely affect the price of flyExclusive’s or Jet.AI’s securities; the risk that Jet.AI stockholder approval of the Transactions is not obtained; the inability to recognize the anticipated benefits of the Transactions; the occurrence of any event, change or other circumstance that could give rise to the termination of the A&R Merger Agreement; changes in general economic conditions; the outcome of litigation related to or arising out of the Transactions, or any adverse developments therein or delays or costs resulting therefrom; the effect of the announcement or pendency of the Transactions on flyExclusive’s or Jet.AI’s respective business relationships, operating results, and businesses generally; costs related to the Transactions; that the price of flyExclusive’s or Jet.AI’s securities may be volatile due to a variety of factors, including flyExclusive’s or Jet.AI’s inability to implement their respective business plans or exceed their financial projections; and the ability to implement business plans, forecasts, and other expectations after the completion of the Transactions, and identify and realize additional opportunities.

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of flyExclusive’s Annual Report on Form 10-K filed with the SEC on May 1, 2024, the “Risk Factors” section of Jet.AI’s Annual Report on Form 10-K filed with the SEC on April 1, 2024 (as amended on April 29 and August 15, 2024), the registration statement on Form S-4, the proxy statement/prospectus and certain other documents filed or that may be filed by flyExclusive or Jet.AI from time to time with the SEC following the date hereof. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and flyExclusive and Jet.AI assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.

Neither flyExclusive nor Jet.AI gives any assurance that flyExclusive or Jet.AI will achieve their expectations.

 

 

 

3

 


 

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

Exhibit
No.

Document

10.1

Amendment No. 1 dated July 30, 2025, to Amended and Restated Agreement and Plan of Merger and Reorganization, dated May 6, 2025, by and among flyExclusive, Inc., FlyX MergerSub, Inc., Jet.AI Inc. and Jet.AI SpinCo, Inc..

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

4

 


 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 30, 2025

FLYEXCLUSIVE, INC.

By:

/s/ Thomas James Segrave, Jr.

Name:

Thomas James Segrave, Jr.

Title:

Chief Executive Officer and Chairman

 

 

 

5

 


FAQ

How many HNGE shares does Atomico own according to the Schedule 13G?

Atomico beneficially owns 6,713,063 Class B shares, convertible into an equal number of Class A shares.

What percentage of Hinge Health does Atomico’s stake represent?

The filing reports an 8.3 % economic ownership based on shares outstanding immediately after the IPO.

Do Atomico’s Class B shares carry additional voting power?

Yes. Each Class B share has 15 votes versus one vote for Class A, giving Atomico outsized voting influence.

Is the investment deemed passive or activist?

The Schedule 13G is filed under Rule 13d-1, indicating a passive investment intent with no activist plans disclosed.

When did the event triggering this filing occur?

The report references the date of event as 23 May 2025, coinciding with Hinge Health’s IPO.
Flyexclusive Inc

NYSE:FLYX

FLYX Rankings

FLYX Latest News

FLYX Latest SEC Filings

FLYX Stock Data

49.29M
10.75M
46.78%
57.63%
1.11%
Airlines
Air Transportation, Nonscheduled
Link
United States
NEW YORK